SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Intellipharmaceutics International Inc. (IPCI)

It has both. Go check for yourself. Most

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
tilator Member Profile
 
Followed By 0
Posts 149
Boards Moderated 0
Alias Born 09/14/17
160x600 placeholder
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 10/20/2017 5:20:34 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 10/18/2017 3:20:22 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/16/2017 6:03:43 AM
Intellipharmaceutics Announces Closing of US$4 Million Financing "GlobeNewswire Inc." - 10/13/2017 5:45:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 10/13/2017 6:04:15 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/12/2017 4:07:48 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/11/2017 8:07:45 AM
Intellipharmaceutics Announces US$4 Million Registered Direct Offering "GlobeNewswire Inc." - 10/11/2017 8:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 10/10/2017 5:25:56 PM
Intellipharmaceutics Announces Third Quarter 2017 Results "GlobeNewswire Inc." - 10/10/2017 5:20:59 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/25/2017 7:12:00 AM
Intellipharmaceutics Receives Complete Response Letter from the FDA for Rexista™ NDA "GlobeNewswire Inc." - 9/25/2017 7:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/20/2017 5:18:47 PM
Intellipharmaceutics Announces Receipt of Nasdaq Notice "GlobeNewswire Inc." - 9/20/2017 5:10:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/5/2017 2:43:50 PM
Intellipharmaceutics Provides Operational Update "GlobeNewswire Inc." - 9/5/2017 2:35:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 9/1/2017 8:10:22 AM
Intellipharmaceutics Appoints New Chief Financial Officer "GlobeNewswire Inc." - 9/1/2017 8:00:00 AM
Monteverde & Associates PC Invites IntelliPharmaCeutics International Inc. Shareholders with Losses in Excess of $1... "PR Newswire (US)" - 8/15/2017 4:52:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 8/8/2017 3:06:36 PM
Intellipharmaceutics Announces Resignation of Chief Financial Officer "GlobeNewswire Inc." - 8/8/2017 3:00:00 PM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/31/2017 8:10:21 AM
Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported Class Action Lawsuit "GlobeNewswire Inc." - 7/31/2017 8:00:00 AM
Report of Foreign Issuer (6-k) "Edgar (US Regulatory)" - 7/27/2017 6:07:34 AM
Intellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Rexista™ (oxycodone hydrochloride extended rele... "GlobeNewswire Inc." - 7/26/2017 8:15:00 PM
tilator   Friday, 11/10/17 04:50:06 PM
Re: wimuskyfisherman post# 31203
Post # of 31344 
Quote:
It has both. Go check for yourself. Most of those names on that list DO NOT have a generic Seroquel XR approval yet



If you take a second look at the numbers Fred gove us, you will notice Accord has biggest sales. Accord was the first to get generic XR approved a year ago, but it was only 400mg tablet. Accord does not yet have 50mg strength at all.

Lupin has second big sales. It got approval together with IPCI, PAR, Pharmadax and Accord for other strengths. This happened may 17 this year as we all know.

AstraZeneca is of course the original manufacturer and it has had XR version since 2007.

So - IPCI/MNK should be quite much at the same level at least with PAR and Pharmadax. Accord entered market second, but it does not have 50mg strength.

Accord sales is more than 150 times bigger than MNK and Lupin sales is more than 50 times bigger. Even thoug they did have approval the very same day as IPCI.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist